Funding for this research was provided by:
National Cancer Institute (P50CA089019)
Susan G. Komen (IIR13265422)
Received: 29 August 2019
Accepted: 6 February 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The protocol was reviewed and approved by each participating institution, and the study followed the Declaration of Helsinki and good clinical practice guidelines. All patients gave informed consent.
: Not applicable.
: C.V. consulting or advisory board: Daiichi-Sankyo, Genentech (unpaid); research funding (paid to the University of Alabama at Birmingham): Roche, Pfizer, Incyte, Novartis, Pharmacyclics, Tracon, Innocrin, H3 Biomedicine, Zymeworks. A.F.T received support from Genentech to conduct clinical and laboratory research (paid to the University of Alabama at Birmingham). A.F.T. is currently an employee of Seattle Genetics. N.U.L.—consulting or advisory board: Puma, Daiichi-Sankyo, Seattle Genetics, Genentech; research funding (paid to institution): Genentech, Pfizer, Novartis, Seattle Genetics, Array Biopharma. The remaining authors declare that they have no competing interests.